View as Webpage

May 2025 | Volume 21, Issue 5

FEATURED STORY

Dr. Elizabeth Koehne: Newest Urologic Oncologist and Surgeon-Scientist at UW-Madison

Elizabeth (Betsy) Koehne, MD, the newest addition to our urologic oncology faculty, brings expertise, passion, and dedication to patient care, research, and the academic community.


Originally from Kansas City, MO, Dr. Koehne completed medical school at the University of Missouri, residency at Loyola University-Chicago, and urologic oncology fellowship at the University of Washington.

 

Dr. Koehne says UW-Madison’s strong history of innovation and collaborative research made it the ideal place for her to launch her career as a urologic surgeon-scientist.

 

Specializing in treating bladder, prostate, kidney, penile, and testis cancers, Dr. Koehne employs advanced surgical techniques tailored to each patient. She offers traditional open and robotic approaches for procedures like radical cystectomy and plans to soon bring novel techniques to Wisconsin – including robotic retroperitoneal partial nephrectomy for kidney masses and transperineal prostate biopsies.

 

“Taking care of patients during critical times in their lives motivates me to provide the best care today and work to improve outcomes for our patients in the future,” she says.


Dr. Koehne’s research focuses on translational bladder cancer studies, using archived surgical tissues and in vitro models to overcome treatment resistance. Collaborating with veterinary scientists, she is developing organoid models to study rare bladder cancer subtypes. She also plans to explore novel imaging modalities to improve disease staging and participate in clinical trials as her practice grows.

DEPARTMENT NEWS

Daniel Shapiro, MD awarded Early Career Scholar grant through Kidney Cancer Research Program

Daniel Shapiro, MD, FACS was selected to receive an Academy of Kidney Cancer Investigators - Early Career Scholar Award through the Kidney Cancer Research Program within the Department of Defense. This award is a 4-year, $1 million mentored grant to conduct translational research. The project is focused on investigating the immunomodulatory effects of chemokine signaling in renal cell carcinoma.


This grant also provides a unique, interactive virtual academy offering intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The program aims to cultivate future leaders in kidney cancer research.

RECENT EVENTS

May is Bladder Cancer Awareness Month

Each May, Bladder Cancer Awareness Month brings attention to a disease that affects tens of thousands of people every year, yet often goes underrecognized in public discourse. The month serves as an important time to educate, support those affected, and encourage early detection efforts.


Understanding Bladder Cancer

Bladder cancer is the sixth most common cancer in the United States, with over 80,000 new cases diagnosed annually. It occurs when malignant cells form in the tissues of the bladder, which stores urine before it exits the body. The most common type is urothelial carcinoma, but other, less common types also exist.


Key Risk Factors

  • Smoking: The leading risk factor, as carcinogens in tobacco are excreted in urine and can damage the bladder lining.
  • Chemical exposure: Certain industrial chemicals used in dye, rubber, and leather industries increase risk.
  • Age and gender: The disease is more common in men and in people over the age of 55.
  • Chronic bladder conditions: Recurrent infections or long-term catheter use may also elevate risk.


Tune in to UW Urology's WInnovations Podcast!

X  Facebook  YouTube  Instagram